Nanotechnology for Delivery of Drugs to the Brain for Epilepsy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
SummaryEpilepsy results from aberrant electrical activity that can affect either a focal area or the entire brain. In treating epilepsy with drugs, the aim is to decrease seizure frequency and severity while minimizing toxicity to the brain and other tissues. Antiepileptic drugs (AEDs) are usually administered by oral and intravenous routes, but these drug treatments are not always effective. Drug access to the brain is severely limited by a number of biological factors, particularly the blood—brain barrier, which impedes the ability of AEDs to enter and remain in the brain. To improve the efficacy of AEDs, new drug delivery strategies are being developed; these methods fall into the three main categories: drug modification, blood—brain barrier modification, and direct drug delivery. Recently, all three methods have been improved through the use of drug-loaded nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Protein—surface interactions in the presence of polyethylene oxide
Jeon, S. I., Lee, J. H., Andrade, J. D., & De Gennes, P. G. (1991) · Journal of Colloid and Interface Science · doi:10.1016/0021-9797(91)90043-8 · Cited by 1,523
Liposomes in drug delivery: Progress and limitations
Sharma, A. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00135-x · Cited by 1,253 · cited 1×
“Another advantage of NPs is their potential to produce sustained and controlled release of the drug over time; liposomes generally do not have this potential, although a few studies claim that it is possible to tailor liposomes to release drugs in a sustained fashion.(13,14) Both NPs and liposomes protect drugs from i…”
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 2×
“In this case, it is speculated that the polysorbate 80 coating on the NPs binds to apolipoproteins B and E when it comes in contact with blood.(42) This newly formed lipoprotein coat, which is made up of natural lipoproteins, might mediate transport across the BBB via the low-density lipoprotein receptors on brain cap…”
Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy
van Vliet, E. A., da Costa Araujo, S., Redeker, S., van Schaik, R., Aronica, E., & Gorter, J. A. (2007) · Brain · doi:10.1093/brain/awl318 · Cited by 775 · cited 1×
“In a recent study using chronic epileptic rats, disruption of the BBB with mannitol once a day for 3 days significantly intensified seizure incidence, compared with the number of seizures observed prior to treatment.(80) Although none of these studies have directly investigated the delivery of AEDs to the brain in com…”
Thorne, R. G., & Nicholson, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509425103 · Cited by 641
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 1×
“nation of desorption, diffusion, and polymer degradation or erosion.(22) In vivo, variables such as the molecular weight of the polymer and mechanism of erosion (bulk or surface) affect the speed of drug release, which can vary from a few hours or days to many months.”
Cited by
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“Among the conventional and recently developed drug delivery strategies, a nano-technological SLN based approach has shown possible advancements in overcoming the existing limitations in the treatment of epilepsy [255].”
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Dendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220
“Similar to ICV, intracerebral or intraparenchymal administration involves the direct delivery of drugs to the brain parenchyma by implantation or injection [65].”
BackgroundMethodRecent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Metadata
- Authors
- Bennewitz, M. F., & Saltzman, W. M.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 6
- Issue
- 2
- Pages
- 323-336
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2013861515
- Cited by
- 142
- References
- 13
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanotechnology for Delivery of Drugs to the Brain for Epilepsy. https://app.cochat.ai/papers/10.1016/j.nurt.2009.01.018
- The paper
- Bennewitz, M. F., & Saltzman, W. M. (2009). Nanotechnology for Delivery of Drugs to the Brain for Epilepsy. Neurotherapeutics. https://doi.org/10.1016/j.nurt.2009.01.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.